$LXRX

Lexicon (LXRX) discussed its Q2 2026 earnings call, focusing on sotagliflozin. The company said SONATA-HCM enrollment is complete and the trial was overenrolled, with top-line results expected in Q1 2027. For Zynquista, Lexicon said FDA resubmission criteria may be met after STENO1 reaches exposure targets by end of August, targeting an NDA resubmission in Q4 2026. It also noted Viatris regulatory progress for sotagliflozin and Novo Nordisk’s Phase I for 9851.

LEXICON PHARMACEUTICALS, INC. (LXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pressreleaseearningsq208-0.htm EX-99.1 Document Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities f

Lexicon Pharmaceuticals (LXRX) completed patient randomization in its pivotal Phase 3 SONATA HCM trial of sotagliflozin for obstructive and non obstructive hypertrophic cardiomyopathy, with a key readout expected in early 2027. The stock closed at $2.34, up 50.97% over 90 days and 105.26% year to date. Simply Wall St cites a $3.77 fair value vs $2.34 close.

Lexicon (LXRX) reported Q1 2026 revenue of $21.1M, up from $1.3M, driven by two $10M Novo Nordisk milestone payments and $1.1M INPEFA sales. R&D fell to $12.8M and SG&A to $9.2M. Net loss narrowed to $1.0M. Cash rose to $199.7M after a capital raise and $100M Hercules Capital refinancing; total debt fell to $49.7M. SONATA Phase III enrollment targets 500 patients by midyear; Zynquista NDA resubmission is on track for midyear.

Lexicon Pharmaceuticals Inc. reported a Q1 2026 revenue of $21.1 million, a substantial increase from $1.3 million year-over-year, largely due to a $20.0 million milestone payment from its Novo Nordisk partnership. The company significantly reduced its net loss to $1.0 million and strengthened its financial position with $199.7 million in cash and a new $100 million loan facility. Lexicon is also advancing its clinical pipeline with studies for sotagliflozin and pilavapadin, and plans to resubmit its NDA for ZYNQUISTA.

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is highlighted as a fast-growing penny stock due to its significant Q1 2026 revenue increase to $21.1 million, driven by a partnership with Novo Nordisk, and a sharp reduction in net loss. The company is advancing several clinical programs, including the Phase 3 SONATA-HCM study and NDA resubmission for ZYNQUISTA, while also preparing for Phase 3 development of pilavapadin for diabetic peripheral neuropathic pain. Lexicon's strengthened financial position with $199.7 million in cash and a new $100 million loan facility further supports its growth trajectory.

This article analyzes the financial performance of Lexicon Pharmaceuticals Inc (LXRX), focusing on its revenue breakdown, profitability margins, and competitive standing. It highlights LXRX's high gross margin but negative operating and net margins, indicating challenges in converting operational activities into shareholder value. The article also benchmarks LXRX against competitors like TBPH and EVO within the market.

Lexicon Pharmaceuticals (NASDAQ:LXRX) stock recently traded above its 200-day moving average, reaching $1.6650 before settling at $1.62. This movement comes amidst mixed analyst ratings, with an average "Hold" rating and a price target of $4.15. Recent insider buying by directors and positive earnings results, where the company surpassed analyst revenue and EPS estimates, also highlight recent activity.

Lexicon Pharmaceuticals has signed three material agreements to raise equity capital. This includes a public offering led by Jefferies and Piper Sandler expected to generate $41.6 million, a private placement with Invus affiliates for $29.12 million in common shares, and a Preferred Stock Purchase Agreement with an Invus affiliate for convertible preferred stock anticipated to add $23.86 million. These actions aim to support liquidity and honor preemptive rights.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Xpeng Inc - ADR ( NYSE:XPEV ) fell sharply in pre-market trading after the company reported third-quarter financial results.